

consists of the same material incorporated by reference in the instant application.

None of these amendments adds new matter.

Applicants request entry of the amendments.

INCORPORATION OF PAGES FROM WO 94/02602

In the June 18, 2002 Office Communication, the Examiner states that the reply filed on April 2, 2002 is not fully responsive to the prior Office Action. Specifically, the Examiner states that the entire disclosure of WO 94/02602 cannot be inserted into the present application because this would render the present specification substantially incomprehensible and confusing. The Examiner further states that with regard to incorporation by reference of essential material, that particular attention should be directed to specific portions of the referenced document where the subject matter being incorporated may be found.

The Examiner suggests that applicants select the sections of WO 94/02602 that specifically relate to the production of transgenic mice comprising the SpeI-SpeI fragment commencing from the VH6 gene and continuing through the human D segment genes, human J segment genes and human constant region genes and into the C δ gene of that locus, wherein said SpeI-SpeI fragment does not include a gamma constant region.

Applicants have amended the specification as suggested by the Examiner. With this amendment, applicants have inserted into the present specification, the sections of WO 94/02602 corresponding to page 54, line 23 to page 55, line 36 and page 71, line 1 to page 72, line 32 of WO 94/02602. These sections of WO 94/02602 refer to Figure 16 of WO 94/02602, which applicants have added to this application as Figure 20. Thus, applicants have amended the paragraphs from

WO 94/02602 added to this application to reflect this change in figure number.

Page 54, line 30 and page 72, line 2 of WO 94/02602 refers to Figure 15 and Figure 8, respectively. In both instances, however, the text should refer to Figure 16. This is an obvious error. Thus, applicants have corrected this inadvertent error herein and have amended these portion of WO 94/02602 to refer to Figure 16 (which has been added to this application as Figure 20).² These pages disclose the production of transgenic mice comprising the SpeI-SpeI fragment described above.

None of the sections of WO 94/02602 inserted into the present application include nucleic acid sequences. Thus, no new sequence listing is required to comply with the rules for submission of nucleic acid and/or amino acid sequences under 37 C.F.R. §§ 1.821-1.825.

In view of the above, applicants submit that the application, as amended, is in condition for allowance, and early, favorable action is solicited.

Respectfully submitted,


Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
R. Minako Pazdera (Reg. No. 46,984)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

² A marked-up version of the paragraphs from WO 94/02602 is attached in the Appendix of Amendments.